Evidence map›Paper›PMID 23990811›Full record

ArticleMicrobial ecology in health and disease2012

Gut indigenous microbiota and epigenetics.

Boris Arkadievich Shenderov

Open access · greenAbstract read
In one paragraph

Article in Microbial ecology in health and disease, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 68 citations in OpenAlex.

  1. Article
  2. Effects ofAnimals : an open access journal from MDPI · 2023
    Article
  3. Review
  4. Review
  5. Article
  6. Reviewing cancer's biology: an eclectic approach.Journal of the Egyptian National Cancer Institute · 2021
    Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Colorectal cancer: The epigenetic role of microbiome.World journal of clinical cases · 2019
    Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. NOD2 mutations and colorectal cancer - Where do we stand?World journal of gastrointestinal surgery · 2016
    Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Boris Arkadievich ShenderovLaboratory of Biology of bifidobacteria, Head of Research Group Probiotics and Functional Foods, Gabrichevsky Research Institute of Epidemiology and Microbiology, Moscow, Russia.
Gabrichevsky Institute of Epidemiology and Microbiology · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This review introduces and discusses data regarding fundamental and applied investigations in mammalian epigenomics and gut microbiota received over the last 10 years. Analysis of these data enabled us first to come to the conclusion that the multiple low-molecular-weight substances of indigenous gut microbiota origin should be considered one of the main endogenous factors actively participating in epigenomic mechanisms that are responsible for the mammalian genome reprograming and post-translated modifications. Gut microecological imbalance caused by various biogenic and abiogenic agents and factors can produce different epigenetic abnormalities and the onset and progression of metabolic diseases associated. The authors substantiate the necessity to create an international project 'Human Gut Microbiota and Epigenomics' that facilitates interdisciplinary collaborations among scientists and clinicians engaged in host microbial ecology, nutrition, metagenomics, epigenomics, and metabolomics investigations as well as in disease prevention and treatment. Some priority scientific and applied directions in the current omic technologies coupled with gnotobiological approaches are suggested that can open a new era in characterizing the role of the symbiotic microbiota small metabolic and signal molecules in the host epigenomics. Although the discussed subject is only at an early stage its validation can open novel approaches in drug discovery studies.

Indexed as

gut microfloramammalian epigenomicsmicrobial small molecules

Identifiers

PMID23990811
PMCPMC3744659
OpenAlexW2141313153

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.